Which Patients Should We Follow up beyond 5 Years after Definitive Therapy for Localized Renal Cell Carcinoma?
- PMID: 25622589
- PMCID: PMC4506106
- DOI: 10.4143/crt.2014.013
Which Patients Should We Follow up beyond 5 Years after Definitive Therapy for Localized Renal Cell Carcinoma?
Abstract
Purpose: Up to 10% of recurrences develop beyond 5 years after curative treatment of localized renal cell carcinoma (RCC). Clinicopathologic features were evaluated to determine which factors are associated with late recurrence.
Materials and methods: A total of 753 patients were diagnosed with localized RCC from January 2000 to June 2008. We enrolled 225 patients who were treated surgically and had a minimal recurrence-free survival of 60 months. Patients who had recurrence beyond 5 years after nephrectomy were defined as the late recurrence group and the remaining patients as the recurrence-free group. Multivariate logistic regression analyses and the Cox proportional hazard model were used for determination of features associated with late recurrence.
Results: In multivariate analyses, age older than 60 (p=0.030), Fuhrman grade ≥ 3 (p=0.042), and pT stage ≥ pT2 (p=0.010) showed statistical association with late recurrence. The Cox proportional hazard model showed significant differences in recurrence-free survival when we classified the patients based on pT2 (p=0.007) and on patient age ≥ 60 years (p=0.039).
Conclusion: Patient age greater than 60 years, Fuhrman grade ≥ 3, and tumor stage ≥ pT2 are independent risk factors of recurrence more than 5 years after surgery in patients with RCC. Therefore, close lifelong follow-up is recommended for patients with these risk factors.
Keywords: Kidney; Neoplasms; Recurrence; Renal cell carcinoma.
Conflict of interest statement
Conflict of interest relevant to this article was not reported.
Figures
Similar articles
-
Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).Eur Urol. 2013 Sep;64(3):472-7. doi: 10.1016/j.eururo.2012.06.030. Epub 2012 Jun 22. Eur Urol. 2013. PMID: 22748912
-
Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma.Urology. 2011 Nov;78(5):1101-6. doi: 10.1016/j.urology.2011.05.012. Epub 2011 Sep 8. Urology. 2011. PMID: 21903243
-
Late recurrence of renal cell carcinoma >5 years after surgery: clinicopathological characteristics and prognosis.BJU Int. 2012 Dec;110(11 Pt B):E553-8. doi: 10.1111/j.1464-410X.2012.11246.x. Epub 2012 May 11. BJU Int. 2012. PMID: 22578274
-
[Relevance of the clinical-pathological predictive factors in force in chromophobe renal cell cancer].Actas Urol Esp. 2012 Oct;36(9):527-31. doi: 10.1016/j.acuro.2011.11.010. Epub 2012 Feb 24. Actas Urol Esp. 2012. PMID: 22365081 Spanish.
-
Long-term survival of patients with unilateral sporadic multifocal renal cell carcinoma according to histologic subtype compared with patients with solitary tumors after radical nephrectomy.Urology. 2004 Sep;64(3):462-7. doi: 10.1016/j.urology.2004.04.016. Urology. 2004. PMID: 15351571 Review.
Cited by
-
Machine Learning Approach to Predict the Probability of Recurrence of Renal Cell Carcinoma After Surgery: Prediction Model Development Study.JMIR Med Inform. 2021 Mar 1;9(3):e25635. doi: 10.2196/25635. JMIR Med Inform. 2021. PMID: 33646127 Free PMC article.
-
Partial nephrectomy versus ablative techniques for small renal masses: a systematic review and network meta-analysis.Eur Radiol. 2019 Mar;29(3):1293-1307. doi: 10.1007/s00330-018-5660-3. Epub 2018 Sep 25. Eur Radiol. 2019. PMID: 30255245
-
Comparison of the Efficacy of Percutaneous Microwave Ablation Therapy versus Laparoscopic Partial Nephrectomy for Early-Stage Renal Tumors.Diagnostics (Basel). 2024 Jul 20;14(14):1574. doi: 10.3390/diagnostics14141574. Diagnostics (Basel). 2024. PMID: 39061711 Free PMC article.
References
-
- Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010;58:398–406. - PubMed
-
- Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009;182:1271–9. - PubMed
-
- Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, et al. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw. 2009;7:618–30. - PubMed
-
- Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, Jewett MA. The natural history of incidentally detected small renal masses. Cancer. 2004;100:738–45. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources